

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of the announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (“**Board**”) of directors (“**Directors**”) of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from 31 March 2023, Ms. Zhou Wan (“**Ms. Zhou**”) has been appointed as an executive Director.

The biographical details of Ms. Zhou are set out below:

Ms. Zhou, aged 33, has been appointed as an executive Director with effect from 31 March 2023. Ms. Zhou joined the Group’s marketing team in February 2012 and has been promoted to the position of the general manager and legal representative of Zhejiang Xin Rui Pharmaceutical Co., Ltd.\* (浙江新銳醫藥有限公司) (“**Zhejiang Xin Rui**”), a wholly-owned subsidiary of the Company, since April 2018.

Ms. Zhou graduated from Zhejiang Chinese Medical University (浙江中醫藥大學) majoring in traditional Chinese pharmacy in 2017. Ms. Zhou has more than 10 years of experience in the pharmaceutical distribution industry in the PRC.

Pursuant to the service contract entered into between Ms. Zhou and the Company, Ms. Zhou has been appointed for a term of two years commencing on 31 March 2023. Her appointment as an executive Director is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws (“**Bye-Laws**”) of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”). Under such service contract, Ms. Zhou is entitled to a salary of HK\$360,000 per annum, which was determined by the Board with reference to her background, experience, qualifications, duties and responsibilities within the Group and the

prevailing market condition. Ms. Zhou is also entitled to a discretionary performance bonus under the service contract as determined by the Board based on performance of the Group and Ms. Zhou. Ms. Zhou also entered into a labour contract with Zhejiang Xin Rui for a term of ten years commencing on 2 April 2018 and pursuant to which she is entitled to a monthly salary of RMB4,100 and a monthly discretionary bonus which is determined by the Board based on her performance. During the year ended 31 December 2022, she has received the total emolument (including salary, bonus and equity-settled share-based payment expense of approximately HK\$1,273,000).

As at the date of this announcement, Ms. Zhou was interested in 15,000,000 shares of the Company by virtue of her holding of certain share options granted to her prior to her appointment as an executive Director.

## **GENERAL**

Save as disclosed above, as at the date of the announcement, (i) Ms. Zhou has not held any other major appointments and qualifications or any directorships in other listed companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) Ms. Zhou does not hold any other positions with the Company or other members of the Group; (iii) Ms. Zhou does not have any relationships with any Directors, senior management, substantial or controlling shareholders (having the meaning ascribed to it under the Listing Rules) of the Company; (iv) Ms. Zhou does not have any interest and short positions in the shares or underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong); and (v) there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules nor any other matters that need to be brought to the attention of the shareholders of the Company in relation to the appointment of Ms. Zhou.

The Board would like to take the opportunity to welcome Ms. Zhou on her new appointment.

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman & Executive Director*

Hong Kong, 31 March 2023

*As of the date of the announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*

\* *For identification only*